TCGA-49-AAR4-01A-12R-A41B-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 51
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.390
- INTERFERON_GAMMA_RESPONSE+0.350
- ALLOGRAFT_REJECTION+0.340
- COAGULATION+0.240
- KRAS_SIGNALING_DN+0.200
- INFLAMMATORY_RESPONSE+0.180
- IL6_JAK_STAT3_SIGNALING+0.170
- MYOGENESIS+0.160
- APICAL_SURFACE+0.140
- SPERMATOGENESIS+0.130
Top 10 suppressed
- MYC_TARGETS_V1-0.620
- PROTEIN_SECRETION-0.590
- MYC_TARGETS_V2-0.570
- UNFOLDED_PROTEIN_RESPONSE-0.520
- OXIDATIVE_PHOSPHORYLATION-0.510
- E2F_TARGETS-0.470
- MTORC1_SIGNALING-0.470
- G2M_CHECKPOINT-0.420
- ANDROGEN_RESPONSE-0.400
- ADIPOGENESIS-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1473590 | GTEX | — | 0.932 |
| 2 | SRR1436966 | GTEX | — | 0.921 |
| 3 | MNG450 | — | — | 0.916 |
| 4 | SRR603658 | GTEX | — | 0.916 |
| 5 | SRR1355373 | GTEX | — | 0.915 |
| 6 | MNG1098 | — | — | 0.911 |
| 7 | SRR934910 | — | — | 0.911 |
| 8 | SRR1341057 | GTEX | — | 0.911 |
| 9 | TCGA-90-A59Q-01A-11R-A26W-07 | — | cohortA1 | 0.910 |
| 10 | SRR1389348 | GTEX | — | 0.909 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.390 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.350 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.180 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.170 | Inavolisib | — uncovered |
| MYOGENESIS | 0.160 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.110 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.100 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| APOPTOSIS | 0.060 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.050 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.030 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.010 | Inavolisib | — uncovered |